Compare Ascendis Pharma A/S (ASND) vs Prudential PLC (PUK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Prudential PLC — how do they compare? Ascendis Pharma A/S trades at $255.46 (market cap $16.67B), while Prudential PLC trades at $27.46 (market cap $34.02B). The key difference: Prudential PLC is far larger — about 2× Ascendis Pharma A/S's market cap, and Prudential PLC pays a 1.94% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | PUK | |
|---|---|---|
Market Cap | $16.67B | $34.02B |
Sector | Health | Financials |
52-Week High | $277.18 | $33.61 |
52-Week Low | $189.74 | $24.98 |
Enterprise Value | $17.04B | $35.46B |
Dividend Yield | — | 1.94% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $255.46, showing minimal daily movement (-0.06%). The stock maintains a bullish technical outlook with strong analyst support (92% buy ratings) and a consensus price target of $309.75, representing 21% upside potential. Recent developments include positive clinical trial updates for TransCon CNP in achondroplasia and inclusion in multiple Russell indexes, signaling growing institutional recognition. Revenue growth has been robust, increasing from $51M in 2022 to $720M in 2025, though the company remains unprofitable with a net loss of $228M in 2025.
ASND presents a growth investment opportunity with multiple product catalysts and improving financial trajectory, though significant risks remain. The company's premium valuation (P/E 29.05, P/S 15.68) reflects high growth expectations, while negative shareholder equity and substantial debt require careful monitoring. Positive cash flow generation since 2024 and upcoming regulatory milestones provide potential upside, but execution risks and clinical trial outcomes could impact shareholder value.
Prudential PLC (PUK) trades at $27.495, down 2.57% today, with a bearish technical signal but strong fundamentals including a P/E of 8.92, net income margin of 14.52%, and robust cash flow from operations of $3.61B in 2024. Recent earnings beat expectations in Q4 2025, though Q4 2024 missed. The stock faces headwinds from China regulatory news impacting Asian operations, but analyst consensus remains 50% buy.
The outlook is mixed: attractive valuation and profitability support upside, but regulatory risks in China and bearish technicals pose near-term challenges. Investors should weigh strong cash generation and earnings beats against geopolitical exposures and market sentiment pressures for balanced risk-reward assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Prudential PLC
Prudential is an Asia and Africa health and life insurance business and is focused on long-term savings. The business is increasingly focusing on digital offerings and creating strong brand equity and relationships with customers of its products through these.
Read more on PUK →
